Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Mercer International Inc. Announces Conference Call for Third Quarter 2025 Results
-
Challenger Center and AIAA Open Nominations for 2026 Trailblazing STEM Educator Award
-
Better Sleep While Traveling
-
Wintrust Financial Corporation Reports Record Net Income
-
What's NEXT Alberta? Albertans Want More RCMP, More Focus on Real Priorities, Confirmed by New Research
-
3 E Network Technology Group Limited Announces Closing of US$1.5 Million Convertible Promissory Note Offering
-
Sportradar to Release Third Quarter 2025 Financial and Operating Results on November 5, 2025
-
Resilient Home Upgrades
-
Papillon Médias Celebrates Over 10 Years of Audiovisual Excellence, Reinforcing Its Role as the Premier High-End Content Creation Agency in Switzerland
-
Bio Usawa Announces Approval of BioUcenta™ by the Rwandan FDA
-
Freshpet, Inc. to Report Third Quarter 2025 Results on Monday, November 3, 2025
-
Commerce to Announce Third Quarter 2025 Financial Results on November 6, 2025
-
Cycurion, Inc. Announces Nasdaq Delisting Determination Letter
-
Columbia Financial, Inc. Announces Financial Results for the Third Quarter Ended September 30, 2025
-
USCB Financial Holdings, Inc. Declares Quarterly Cash Dividend On Common Stock
-
CLEAR and Wellstar Health System Modernize the Patient Experience Using CLEAR1’s Digital Check-In
-
Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)
-
Chijet Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Compliance
-
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
-
Figure Technology Solutions Announces Date for Q3 2025 Earnings
-
Lirum Therapeutics Announces FDA “Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor
-
Lirum Therapeutics Announces FDA “Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor
-
TWFG, Inc. to Announce Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
-
Health Catalyst to Announce Third Quarter 2025 Operating Results and Host Conference Call on Monday, November 10, 2025
-
7 Energy-Saving Tips
-
Ceremonial First Poppy presented to Canada’s Governor General
-
Saga Communications, Inc. Closes on Sale of 22 Tower Sites
-
BrightSpring Announces Secondary Offering of Common Stock and Concurrent Share Repurchase
-
7 Energy-Saving Tips
-
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
-
Fabrinet to Announce First Quarter Fiscal Year 2026 Financial Results on November 3, 2025
-
Getty Images Announces Final Results of Exchange Offer and Consent Solicitation
-
Boston Beer Company Names Phil Hodges Chief Operating Officer
-
Triller Group Receives Nasdaq Delisting Determination Letter for Non-Compliance with Listing Rule 5250(c)(1) and Intends to Request a Hearing before Nasdaq Hearings Panel
-
Cheer Holding Receives Nasdaq Notification of Non-Compliance with Listing Rules 5550(a)(2)
-
Quanex Building Products Appoints Gabriela Garcia as Chief Accounting Officer
-
Atlantic City Public Schools Officially Launches Nation’s First District-Wide Esports Program
-
BrightSpring Health Services, Inc. Reports Preliminary Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
-
Preferred Bank Reports Record Third Quarter Results
-
Gouverneur Bancorp, Inc. Announces Increase in Semi-Annual Cash Dividend
-
SI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025
-
Medallion Financial Corp. to Report 2025 Third Quarter Results on Wednesday, October 29, 2025
-
Cipher Mining Announces Date of Third Quarter 2025 Business Update Conference Call
-
TERRA CLEAN ANNOUNCES LIFE OFFERING
-
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
-
Key Tronic Corporation Announces First Quarter Reporting Date
-
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering
-
PDF Solutions to Report Third Quarter Fiscal 2025 Financial Results on November 6, 2025
-
Tactile Medical to Release Third Quarter of Fiscal Year 2025 Financial Results on November 3, 2025
-
Interparfums, Inc. Reports 2025 Third Quarter Net Sales
